Group 1 - The company, Yidu Tech (02158), announced a share buyback on January 28, repurchasing 121,800 shares at approximately HKD 6 per share, totaling around HKD 730,000. This marks the fourth consecutive trading day of buybacks, with a total of approximately 830,000 shares repurchased and nearly HKD 5 million spent, signaling confidence to the market [1] - The company has achieved significant progress in business expansion and product implementation, with the number of participants in the 2026 "Beijing Universal Health Insurance" exceeding 4.5 million. As the main operating platform for this project for five consecutive years, Yidu Tech demonstrates its operational strength and market recognition [1] - Yidu Tech has made breakthroughs in the application of AI in primary healthcare, with the "General Medicine Diagnosis AI Assistant" developed in collaboration with Chongqing Medical University First Affiliated Hospital being implemented in over 20 grassroots medical institutions in Chongqing since its trial run in May 2025, serving more than 1,000 healthcare professionals [1]

Core Viewpoint - The company, Yidu Tech (02158), is actively engaging in share buybacks to instill market confidence while simultaneously achieving significant progress in business expansion and product implementation [1] Group 1: Share Buyback Activity - On January 28, Yidu Tech announced a share buyback of approximately 121,800 shares at around HKD 6 per share, costing about HKD 730,000 [1] - The company has conducted buybacks for four consecutive trading days, totaling approximately 830,000 shares and nearly HKD 5 million in expenditure [1] Group 2: Business Expansion - The number of participants in the 2026 "Beijing Universal Health Insurance" program, which Yidu Tech operates, has surpassed 4.5 million [1] - Yidu Tech has been the main operating platform for this project for five consecutive years, demonstrating its operational strength and market recognition [1] Group 3: Technological Advancements - Yidu Tech has made breakthroughs in the application of AI in healthcare, specifically with the "General Medicine Diagnosis AI Assistant" developed in collaboration with Chongqing Medical University [1] - Since its trial run in May 2025, the AI assistant has been implemented in over 20 grassroots medical institutions in Chongqing, serving more than 1,000 healthcare professionals [1]

医渡科技(02158)公布，2026年1月29日耗资约72.82万港元回购12.18万股股份。 ...

智通财经APP讯，医渡科技(02158)公布，2026年1月29日耗资约72.82万港元回购12.18万股股份。 ...

格隆汇1月29日丨医渡科技(02158.HK)公告，1月29日耗资72.8万港元回购12.2万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and long-term development [1] Group 1: Share Buyback - On January 28, Yidu Tech announced a share buyback of 204,000 shares at approximately HKD 6 per share, costing around HKD 1.23 million [1] - The company has conducted share buybacks for three consecutive trading days, totaling approximately 709,000 shares repurchased and over HKD 4.2 million spent [1] Group 2: Business Progress - The number of insured individuals under the 2026 Beijing Universal Health Insurance program has surpassed 4.5 million, showcasing the company's operational strength and market recognition [1] - Yidu Tech has been the main operating platform for this project for five consecutive years, contributing to the multi-tiered medical security system in the capital [1] Group 3: International Collaboration and Recognition - The founder and chairman of Yidu Tech, Gong Rujing, attended the 2026 Winter Davos Forum, where a collaboration with Novartis Foundation and the Brunei Ministry of Health was announced for a cardiovascular disease prevention project called CARDIO4Cities [1] - Yidu Tech ranked first in the 2025 Medical Big Data Company Rankings for the seventh consecutive year, reflecting its strong technical foundation, mature product system, and extensive industry experience [1]

智通财经APP获悉，1月28日，医渡科技(02158)再度发布股份回购公告，宣布当日以每股约6港元的价格 回购20.4万股，耗资约123万港元。至此，公司已连续三个交易日密集实施回购操作，合计回购约70.9万 股，累计耗资超420万港元，持续以真金白银释放对公司内在价值的认可及长远发展的坚定信心。 除资本端积极动作外，公司主营业务亦传来进展。公司主运营的2026年度北京普惠健康保参保人数已突 破450万，作为连续五年担任该项目主运营平台的企业，医渡科技凭借专业的运营服务与技术赋能，持 续助力首都多层次医疗保障体系建设，进一步彰显了其业务实力与市场认可度。 此前消息显示，医渡科技创始人、董事长宫如璟近期受邀出席2026冬季达沃斯论坛，期间诺华基金会、 文莱卫生部与公司旗下EVYD公司三方合作消息宣布，将联合实施数智驱动的心血管疾病防控项目 CARDIO4Cities，进一步拓展国际合作版图。与此同时，行业权威榜单《2025医疗大数据企业排行榜》 正式揭晓，医渡科技凭借深厚的技术积淀、成熟的产品体系与丰富的行业落地经验，连续第七年斩获榜 首，持续领跑医疗大数据赛道。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年1月28日该公司斥资122.57万港元回购20.44万 股，回购价格为每股5.98-6.00港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...